USA – Auron Therapeutics, a Newton, Mass.-based biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer, closed its $48 million Series A financing round.
The round was led by DCVC Bio with additional support from new investors Mubadala Capital and Apollo Health Ventures, and from existing investors Arkin Bio Ventures, Polaris Partners, Qiming Venture Partners USA, Eli Lilly and Company, BrightEdge (the investment arm of the American Cancer Society), Franklin Berger and Casdin Capital. Dr. Eric Shiozaki, Ph.D., Partner at DCVC Bio and Dr. Alexandra Cantley, Ph.D., Partner at Polaris Partners will be joining the Company’s Board of Directors. Dr. Rami Hannoush, Ph.D., Partner at Mubadala Capital, and Dr. Marianne Mertens, Ph.D., Partner at Apollo Health Ventures, will join the Company as Board observers. The company intends to use the funds to advance the lead program toward clinical development and drive additional programs into drug discovery. Funds will also be used to expand the proprietary, machine learning-based computational platform, AURigin, that is used to identify novel drug targets, and add personnel to support and accelerate research and development.Led by Dr. Yen, founder and CEO, Auron Therapeutics is shifting the paradigm of cancer treatment to target key drivers of dysregulated differentiation and cellular plasticity in tumors. This type of therapy, called differentiation therapy, offers lifesaving treatments for patients and their families.20/07/2022
